Company Description

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.

The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes.

Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Forte Biosciences, Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	22
CEO	Paul A. Wagner

Contact Details

Address: 3060 Pegasus Park Drive, Building 6 Dallas, Texas 75247 United States
Phone	310 618 6994
Website	fortebiorx.com

Stock Details

Ticker Symbol	FBRX
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1419041
CUSIP Number	34962G109
ISIN Number	US34962G2084
Employer ID	26-1243872
SIC Code	2834

Key Executives

Name	Position
Dr. Paul A. Wagner Ph.D.	Chief Executive Officer, President and Chairman
Antony A. Riley CPA	Chief Financial Officer
Dr. Barbara K. Finck M.D.	Acting Senior Medical Clinician and Director
Christopher Roenfeldt	Chief Operating Officer

Latest SEC Filings

Date	Type	Title
Jun 10, 2026	EFFECT	Notice of Effectiveness
Jun 8, 2026	SCHEDULE 13G	Filing
Jun 8, 2026	S-3/A	[Amend] Registration statement under Securities Act of 1933
Jun 2, 2026	S-3	Registration statement under Securities Act of 1933
Jun 2, 2026	S-8	Securities to be offered to employees in employee benefit plans
Jun 2, 2026	8-K	Current Report
May 15, 2026	SCHEDULE 13G/A	Filing
May 15, 2026	SCHEDULE 13G/A	Filing
May 15, 2026	SCHEDULE 13G	Filing
May 15, 2026	SCHEDULE 13G/A	Filing

View All SEC Filings